Revreboot,
the first obvious positive is direction of Fonda revenues to ACL holders rather than to Oncology development.
The corresponding down side is dilution in our holding in the new oncology spin off.
the second positive is potential revenues from HyAct at half a billion pa
the third positive is a buy in price that is seemingly a bargain. Those that got in at .25c this morning are laughing I'm sure.
There was always going to be dilution so we should all just move on a get set.
Cheers
Mulac
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable